Neurogene Inc.
NGNE
$15.22
-$0.29-1.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 925.00K | 925.00K | 925.00K | 925.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 925.00K | 925.00K | 925.00K | 925.00K | -- |
| Cost of Revenue | 65.14M | 60.83M | 57.66M | 52.98M | 47.56M |
| Gross Profit | -64.21M | -59.90M | -56.74M | -52.06M | -47.56M |
| SG&A Expenses | 25.53M | 22.61M | 19.00M | 16.72M | 13.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.67M | 83.44M | 76.66M | 69.70M | 61.24M |
| Operating Income | -89.75M | -82.51M | -75.74M | -68.77M | -61.24M |
| Income Before Tax | -80.87M | -75.14M | -53.25M | -47.61M | -40.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -80.87 | -75.14 | -53.25 | -47.61 | -40.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.87M | -75.14M | -53.25M | -47.61M | -40.98M |
| EBIT | -89.75M | -82.51M | -75.74M | -68.77M | -61.24M |
| EBITDA | -86.56M | -79.27M | -72.46M | -65.48M | -57.93M |
| EPS Basic | -4.36 | -4.29 | 78.14 | 46.67 | 21.07 |
| Normalized Basic EPS | -2.73 | -2.68 | -15.63 | -35.30 | -51.30 |
| EPS Diluted | -4.37 | -4.29 | -0.26 | -31.73 | -57.32 |
| Normalized Diluted EPS | -2.73 | -2.68 | -2.55 | -22.22 | -38.22 |
| Average Basic Shares Outstanding | 74.36M | 70.27M | 51.44M | 34.93M | 18.44M |
| Average Diluted Shares Outstanding | 74.36M | 70.27M | 68.10M | 51.59M | 35.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |